Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

The materials for DUPIXENT contained in this virtual exhibition are approved for use only in the United States of America. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the full Prescribing Information and/or the Summary of Product Characteristics (SmPC).

EXPLORE THE FIRST AND ONLY BIOLOGIC FDA APPROVED IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (CRSwNP)

 
 
Listen to experts

Dr Yen: Discussing CRSwNP with prior surgery


Dr Yen & Dr Ramirez: Discussing CRSwNP and comorbid NSAID-ERD


Dr Ramirez: Discussing CRSwNP and history of asthma


Dr Sher: CRSwNP endpoints and data


Dr Sher: CRSwNP pooled analyses

 
 
PATIENT BUILDER

Build a patient to see if DUPIXENT is indicated as a CRSwNP treatment option

 
 
EXPLORE THE MOA, EFFICACY & SAFETY PROFILE

View the science behind the mechanism of action of DUPIXENT


Explore DUPIXENT's efficacy and safety profile

 
 
EXPLORE CRSwNP DATA

Download a resource about CRSwNP patients with previous sino-nasal surgery


Download a resource about CRSwNP patients with comorbid asthma or NSAID-ERD

 
 
DUPIXENT MyWay®

Enrollment Video: Information to help your appropriate patients with the enrollment process


Delivery Video: See how your appropriate patients can access DUPIXENT


Prior Authorization Checklist


Prior Authorization Roadmap

 
 
DOSING AND ADMINISTRATION

Dosing Card


Pre-filled Pen Flashcard

 
 
VIEW upper Airway
Inflammation

Download this asset to see the potential of DUPIXENT

Transcript / Video Title

View Transcript

Transcript Text.

SWIPE TO EXPLORE

Reference:

  1. DUPIXENT Prescribing Information.
  2. Sino-Nasal Outcome Test (SNOT-22). St Louis, MO: Washington University; 2006.
  3. Data on file, Sanofi US. Clinical overview (chronic rhinosinusitits with nasal polyposis). 2018.
  4. Data on file, Sanofi US. LIBERTY NP SINUS-52, CSR. 2018.